文献速递眼底病与葡萄膜炎

美国直接面向消费者营销网站提供眼部疾病细胞疗法诊所的最新进展

Update on "Cell Therapy" Clinics Offering Treatments of Ocular Conditions Using Direct-To-Consumer Marketing Websites in the U.S.
PubMed 文献 · Am J Ophthalmol · 2024-06-15

该趋势研究通过关键词网络搜索评估美国直接面向消费者营销的非FDA批准细胞疗法(NFACT)诊所,发现2019年至2023年间诊所从62家降至18家、公司从39家降至13家,但2019年数据显示此类疗法仍持续存在,尽管缺乏高质量证据且与严重视力丧失相关。

要点

  • 2019年至2023年美国NFACT诊所从62家降至18家,公司从39家降至13家。
  • 最常宣传的眼部疾病为年龄相关性黄斑变性(2019年72%,2022年92%)。
  • 自体脂肪来源干细胞是两项分析中最常用的细胞类型。

核心结论

  • 2019年美国直接面向消费者营销NFACT的公司持续存在,尽管缺乏高质量临床证据、部分治疗与严重视力丧失相关且FDA监管和法律行动增加。
  • 2022年诊所和公司数量减少,但其持续存在提醒需持续关注,眼科协会需继续倡导以保护患者免受潜在掠夺性组织侵害。

研究设计与样本

  • 趋势研究,基于公司公开网站信息,纳入美国使用直接面向消费者营销并广告眼部疾病治疗的公司。
  • 通过系统广泛的关键词网络搜索识别、记录和分析截至2022年8月提供NFACT治疗眼部疾病的美国商业网站。

主要发现

  • 从2017年分析到2019年分析,NFACT诊所数量从76家降至62家,公司从40家降至39家。
  • 2022年分析显示NFACT诊所从2019年的62家降至2023年的18家,公司从39家降至13家。
  • 2019年和2022年最常提及的眼部疾病均为年龄相关性黄斑变性(2019年72%,2022年92%)。
  • 诊所数量最多的州为德克萨斯州(2019年12家;2022年5家)。
  • 两项分析中最常用的细胞类型均为自体脂肪来源干细胞。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To assess the scope of U.S.-based companies advertising and administering non-Federal Drug Administration (FDA) approved cell-based therapy (herein called NFACT) for ocular conditions based on information from companies' public websites after the FDA's legal actions against specific NFACT clinics in 2018 and 2019. Current findings are compared to previously published data from 2017. DESIGN: Trend study looking at U.S.-based companies that use direct-to-consumer marketing and have websites advertising therapy for ocular conditions. METHODS: A systematic and extensive keyword-based Internet search was utilized to identify, document, and analyze U.S. business websites offering NFACT for ocular conditions as of August 2022. Main outcomes measured include, clinic locations, marketed ocular conditions, types of NFACT offered, source of stem cells used, routes of administration, and treatment costs. RESULTS: From the prior analysis in 2017 to the 2019 analysis, there was a decrease in the number of NFACT clinics from 76 to 62 and companies from 40 to 39. Given the concerning persistence of NFACTs in August 2019 an additional analysis was performed in 2022 which showed a drastic decrease in NFACT clinics from 62 in 2019 to 18 in 2023 and from 39 companies to 13 in 2023. In both 2019 and 2022, the most commonly referenced ocular condition was age-related macular degeneration (2019-72%, 2022-92%). The state with the most clinics was in Texas (2019-12; 2022-5). Autologous adipose-derived stem cells were the most common cell type used in both analyses. CONCLUSIONS: In 2019 U.S.-based direct-to-consumer companies marketing NFACT persisted despite (1) a lack of high-quality clinical evidence supporting the efficacy of these procedures, (2) the association of some of these treatments with severe vision loss, and (3) increasing FDA oversight and recent legal action. In 2022 the number of clinics and companies decreased, but their persistence is a reminder that continued concern is necessary and ophthalmic associations need to continue advocacy efforts to protect patients from these potentially predatory organizations.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Kalavar M, Lovett EA, Nicholas MP, et al. Update on "Cell Therapy" Clinics Offering Treatments of Ocular Conditions Using Direct-To-Consumer Marketing Websites in the U.S. Am J Ophthalmol. 2024. PMID: 38880376. doi:10.1016/j.ajo.2024.06.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。